NICE DSU TECHNICAL SUPPORT DOCUMENT 19 : PARTITIONED SURVIVAL ANALYSIS FOR DECISION MODELLING IN HEALTH CARE : A CRITICAL REVIEW REPORT BY THE DECISION SUPPORT UNIT 2 June 2017

[1]  D. Kleinbaum,et al.  Survival Analysis: A Self-Learning Text. , 1996 .

[2]  R. Gelber,et al.  Quality adjusted survival analysis. , 1990, Statistics in medicine.

[3]  Nicky J Welton,et al.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves , 2012, BMC Medical Research Methodology.

[4]  Yohann Foucher,et al.  Cost‐effectiveness analysis in colorectal cancer using a semi‐Markov model , 2007, Statistics in medicine.

[5]  P Glasziou,et al.  Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Martin Schumacher,et al.  Multi-state model for studying an intermediate event using time-dependent covariates: application to breast cancer , 2013, BMC Medical Research Methodology.

[7]  Keith R. Abrams,et al.  Adjusting Survival Time Estimates in the Presence of Treatment Switching , 2014 .

[8]  R. Goeree,et al.  Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes , 2016, Journal of medical economics.

[9]  M. Hernán,et al.  Why post‐progression survival and post‐relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials , 2015, International journal of cancer.

[10]  G. Skrepnek,et al.  Quality‐adjusted time without symptoms or toxicity (Q‐TWiST): patient‐reported outcome or mathematical model? A systematic review in cancer , 2015, Psycho-oncology.

[11]  Paul Tappenden,et al.  NICE DSU TECHNICAL SUPPORT DOCUMENT 13 : IDENTIFYING AND REVIEWING EVIDENCE TO INFORM THE CONCEPTUALISATION AND POPULATION OF COST-EFFECTIVENESS MODELS , 2012 .

[12]  Nicholas R Latimer,et al.  Response to “Survival Analysis and Extrapolation Modeling of Time-to-Event Clinical Trial Data for Economic Evaluation: An Alternative Approach” by Bagust and Beale , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.

[13]  H Putter,et al.  Tutorial in biostatistics: competing risks and multi‐state models , 2007, Statistics in medicine.

[14]  S. Haneuse,et al.  Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research. , 2016, Journal of the National Cancer Institute.

[15]  Keith R Abrams,et al.  Adjusting Survival Time Estimates to Account for Treatment Switching in Randomized Controlled Trials—an Economic Evaluation Context , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.

[16]  Claire Williams,et al.  Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial , 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

[17]  Geert Verbeke,et al.  Joint modeling of progression‐free survival and death in advanced cancer clinical trials , 2010, Statistics in medicine.

[18]  Martin T. Wells,et al.  Nonparametric estimation of successive duration times under dependent censoring , 1998 .

[19]  Nicholas R Latimer,et al.  Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[20]  Andrea Manca,et al.  NICE DSU TECHNICAL SUPPORT DOCUMENT 17: THE USE OF OBSERVATIONAL DATA TO INFORM ESTIMATES OF TREATMENT EFFECTIVENESS IN TECHNOLOGY APPRAISAL: METHODS FOR COMPARATIVE INDIVIDUAL PATIENT DATA , 2015 .

[21]  Carmen Cadarso-Suárez,et al.  Multi-state models for the analysis of time-to-event data , 2009, Statistical methods in medical research.

[22]  Hein Putter,et al.  Special Issue about Competing Risks and Multi-State Models , 2011 .

[23]  Luís Meira-Machado,et al.  Nonparametric estimation of conditional transition probabilities in a non-Markov illness-death model , 2014, Computational Statistics.

[24]  Claire Williams,et al.  Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling , 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

[25]  U. Siebert,et al.  Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example. , 2015, Critical reviews in oncology/hematology.

[26]  Mark Sculpher,et al.  Cost-Effectiveness Analysis of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

[27]  Kristine R Broglio,et al.  Detecting an overall survival benefit that is derived from progression-free survival. , 2009, Journal of the National Cancer Institute.

[28]  Nicky J Welton,et al.  Multiparameter evidence synthesis in epidemiology and medical decision-making , 2008, Journal of health services research & policy.

[29]  N. Welton,et al.  Estimation of Markov Chain Transition Probabilities and Rates from Fully and Partially Observed Data: Uncertainty Propagation, Evidence Synthesis, and Model Calibration , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

[30]  J. Jansen.  Network meta-analysis of survival data with fractional polynomials , 2011, BMC medical research methodology.

[31]  M. Sculpher,et al.  Decision Modelling for Health Economic Evaluation , 2006 .

[32]  W. Henley,et al.  Improved curve fits to summary survival data: application to economic evaluation of health technologies , 2011, BMC Medical Research Methodology.

[33]  W. D. Ray.  4. Modelling Survival Data in Medical Research , 1995 .

[34]  A E Ades,et al.  Meta‐analysis of mixed treatment comparisons at multiple follow‐up times , 2007, Statistics in medicine.

[35]  A. Tsodikov,et al.  Joint modeling approach for semicompeting risks data with missing nonterminal event status , 2014, Lifetime data analysis.

[36]  Matt Stevenson,et al.  Cost-Effectiveness Modelling Using Patient-Level Simulation , 2014 .

[37]  Adrian Bagust,et al.  Survival Analysis and Extrapolation Modeling of Time-to-Event Clinical Trial Data for Economic Evaluation , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.

[38]  J R Beck,et al.  Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[39]  J. Hornberger,et al.  The cost‐effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective , 2010, European journal of haematology.

[40]  Christopher H. Jackson,et al.  Multi-State Models for Panel Data: The msm Package for R , 2011 .

[41]  Stirling Bryan,et al.  Modelling in the economic evaluation of health care: selecting the appropriate approach , 2004, Journal of health services research & policy.

[42]  Hein Putter,et al.  Estimation and Prediction in a Multi‐State Model for Breast Cancer , 2006, Biometrical journal. Biometrische Zeitschrift.

[43]  J. Peters,et al.  Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[44]  D. Owens,et al.  State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[45]  Philippe Lambin,et al.  Multistate Statistical Modeling , 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

[46]  Andrew C Titman,et al.  Model diagnostics for multi-state models , 2010, Statistical methods in medical research.

[47]  T. Delea,et al.  Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in Canada. , 2014, Current oncology.

[48]  Keith R Abrams,et al.  Using electronic health records to predict costs and outcomes in stable coronary artery disease , 2016, Heart.

[49]  S. Chick,et al.  A taxonomy of model structures for economic evaluation of health technologies. , 2006, Health economics.

[50]  Nicky J. Welton,et al.  Extrapolation of Survival Curves from Cancer Trials Using External Information , 2016, Medical decision making : an international journal of the Society for Medical Decision Making.